Solid Tumor Market: By Tumor Type, By Therapy Type, By Drug Class, By Route of Administration By End Users, and Region Forecast 2020-2031

Solid Tumor Market Size, Share, Growth, Trends, and Global Industry Analysis: By Tumor Type (Benign Tumor and Malignant Tumor), By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy, Tyrosine Kinase Inhibitors, Proteasome Inhibitor, Hedgehog Pathway Inhibitor, and Others), By Drug Class (Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors, Proteasome Inhibitors, Monoclonal Antibodies, and Others), By Route of Administration (Oral, Parenteral, and Others) By End Users (Hospitals, Specialty Clinics, Homecare, and Others), and Region Forecast 2020-2031

Solid Tumor Market size was valued at US$ 4,832.3 million in 2024 and is projected to reach US$ 5,589.0 million by 2031 at a CAGR of 2.1% from 2025-2031. Moreover, the U.S. Solid Tumor Market is projected to grow significantly, reaching an estimated value of US$ 1,743.8 Million by 2031. The market focuses on the diagnosis, treatment, and management of solid tumors, which are abnormal masses of tissue that do not contain liquid or cyst areas.

The market is being primarily driven by the rising global cancer burden, particularly in high-incidence cancers like breast, lung, colorectal, and prostate. Aging populations, lifestyle risk factors, and improved diagnostic access have led to a growing patient pool, prompting increased investments in early detection, targeted therapies, and precision oncology. A major trend shaping the market is the integration of advanced diagnostics, especially liquid biopsies and AI-powered tools, which enable early detection, real-time monitoring, and personalized treatment decisions. These innovations are redefining clinical workflows and accelerating the shift toward data-driven, individualized care.

Expansion of immuno-oncology into early-stage cancers and new tumor types, supported by growing approvals for checkpoint inhibitors, ADCs, and tumor-agnostic drugs provides opportunity for the market. Additionally, biosimilars, mRNA cancer vaccines, and digital therapeutics are creating new growth avenues. However, high treatment costs remain a major restraint, limiting access, especially in low- and middle-income countries. Even in developed markets, cost-effectiveness concerns impact reimbursement and adoption. Other challenges include limited biomarker infrastructure and disparities in oncology workforce distribution. Despite these barriers, the market’s trajectory remains positive, propelled by innovation, policy support, and the urgent need for effective cancer solutions.

Facts & Figures

  • Rising Global Prevalence of Cancer: The increasing prevalence of solid tumors, such as breast, lung, colorectal, and prostate cancers, is the primary demand driver. Aging populations, sedentary lifestyles, and environmental exposure continue to fuel cancer rates worldwide. For instance, according to GLOBOCAN 2024, global cancer cases are expected to reach over 30 million annually by 2040, up from 20 million in 2020, reinforcing sustained market demand for diagnostics and therapeutics.
  • Technological Advancements in Diagnostics (Liquid Biopsies & AI): Advanced diagnostics like ctDNA-based liquid biopsies and AI-enabled imaging are transforming early detection, treatment planning, and recurrence monitoring for solid tumors. For instance, in June 2025, Guardant Health partnered with Pfizer to integrate its Infinity ctDNA platform into global trials, showing strong pharma confidence in non-invasive, precision-based diagnostics.
  • Expansion of Immuno-Oncology into Early-Stage Settings: Checkpoint inhibitors and immunotherapies, once reserved for metastatic settings, are increasingly being approved for adjuvant and neoadjuvant use, expanding the addressable patient pool. For instance, at ASCO 2025, early-stage lung and bladder cancers showed strong response rates to PD-1/PD-L1 inhibitors. Approvals for earlier use of nivolumab and pembrolizumab now cover post-surgical and pre-operative settings, broadening commercial potential.
  • Growing Focus on Emerging Markets and Biosimilars: With cancer care expanding in Asia, Latin America, and Africa, biosimilars of high-cost biologics are creating more affordable access to oncology treatments, especially in resource-limited settings. For instance, recently, Zydus Lifesciences partnered with Agenus to co-develop and commercialize biosimilar-grade immune checkpoint antibodies in India and the U.S., boosting scale and affordability in key geographies.

Key Developments

  • In June 2025, BioNTech & Bristol Myers Squibb partnered on BNT327. A landmark co-development and co-commercialization agreement worth $11.1?billion focuses on a next-gen bispecific antibody for multiple solid tumors.
  • In June 2025, BioNTech acquired CureVac for $1.25?billion. This all?stock merger strengthens BioNTech’s mRNA-based oncology pipeline beyond vaccines.
  • In June 2025, QIAGEN & Tracer Biotechnologies form an MRD partnership
    They collaborated to develop blood-based MRD tests for solid tumors on QIAcuity, underscoring diagnostic innovation.
  • In March 2025, AstraZeneca acquired EsoBiotec for up to $1?billion. Strengthening its in vivo CAR?T cell therapy capabilities for simpler cancer treatments.

Solid Tumor Market Segmentation

Based on the tumor type

  • Benign Tumor
  • Malignant Tumor

Based on tumor type, the malignant tumor segment holds the largest market share in the market. This is primarily due to the high prevalence of cancers such as breast, lung, colorectal, and prostate, which are classified as malignant and often require extensive treatment involving surgery, chemotherapy, radiotherapy, and targeted therapies. The rising global cancer burden, along with advancements in diagnostics and oncology drugs, further drives the dominance of this segment. On the other hand, benign tumors, though common, typically do not pose immediate life-threatening risks and require less aggressive treatment, resulting in a comparatively smaller market share.

Based on the therapy type

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Tyrosine kinase inhibitors
  • Proteasome inhibitor
  • Hedgehog pathway inhibitor
  • Others

Based on therapy type, targeted therapy holds the largest market share in the market due to its high efficacy, reduced side effects, and growing use across major cancers like breast, lung, and colorectal. Targeted therapies, including monoclonal antibodies and small molecules, are designed to interfere with specific molecular targets driving tumor growth, making them essential in precision oncology. Drugs like trastuzumab (HER2+ breast cancer) and osimertinib (EGFR-mutated NSCLC) have become standard-of-care treatments. Hedgehog pathway inhibitors represent the smallest market segment, largely due to their limited indications (e.g., basal cell carcinoma) and narrow patient base.

Based on the drug class

  • Alkylating Agents
  • Antimetabolites
  • Topoisomerase Inhibitors
  • Proteasome Inhibitors
  • Monoclonal Antibodies
  • Others

Based on drug class, monoclonal antibodies hold the largest market share in the market due to their targeted mechanism of action, proven clinical efficacy, and broad application across multiple high-incidence cancers such as breast, lung, and colorectal. These biologics offer greater specificity and fewer off-target effects compared to traditional chemotherapeutic agents, making them a preferred choice in modern oncology. Blockbuster drugs like trastuzumab (Herceptin), bevacizumab (Avastin), and pembrolizumab (Keytruda) have set the benchmark for monoclonal antibody success in solid tumors. In contrast, proteasome inhibitors, primarily used in hematologic malignancies, hold the smallest share in the solid tumor segment due to their limited approval and modest results in solid tumor indications.

Based on the route of administration

  • Oral
  • Parenteral
  • Others

Based on the route of administration, parenteral administration holds the largest market share in the global solid tumor market. Most monoclonal antibodies, chemotherapies, and immunotherapies are administered intravenously or subcutaneously in clinical settings to ensure precise dosing, rapid action, and controlled bioavailability, especially for aggressive or advanced-stage cancers. Hospital infrastructure and infusion centers are well-equipped for parenteral regimens, which are preferred in both first-line and combination therapies. However, the oral segment is steadily growing due to patient preference for convenience and better compliance, particularly with targeted therapies and tyrosine kinase inhibitors, though it still accounts for a smaller overall share.

Based on the end users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Based on end users, hospitals hold the largest market share in the global solid tumor market due to their comprehensive oncology infrastructure, availability of multidisciplinary care, and ability to administer complex treatments such as parenteral chemotherapy, immunotherapy, and advanced diagnostics. Hospitals are the primary setting for cancer diagnosis, surgery, infusion therapies, and clinical trials, making them central to solid tumor management. They also serve as referral centers for severe and late-stage cases requiring intensive care. While specialty clinics are expanding in urban areas with outpatient services and targeted therapies, and home care is gaining traction for oral medications and palliative care, these segments still hold a smaller share compared to hospital-based oncology care.

Solid Tumor Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

2.1%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Solid Tumor Market

Drivers

One key driver of the market is the increasing global cancer burden, particularly the rising incidence of solid tumors such as breast, lung, colorectal, and prostate cancers. With aging populations, sedentary lifestyles, rising tobacco and alcohol use, and exposure to environmental carcinogens, the number of diagnosed cancer cases continues to grow, driving demand for diagnostics, targeted therapies, and advanced oncology treatments. This surge in patient volume compels healthcare systems and pharmaceutical companies to invest in early detection technologies and next-generation treatments such as immunotherapies, monoclonal antibodies, and precision medicine. Additionally, expanding health insurance coverage in emerging markets and growing patient awareness are accelerating treatment adoption. While the rising cancer incidence remains the primary growth engine, other contributing drivers include advancements in tumor biology research, approvals of novel biologics and biosimilars, increasing investments in oncology clinical trials, and the integration of artificial intelligence in oncology diagnostics and personalized therapy planning.

Restraints

A prominent restraint in the market is the high cost of advanced therapies, particularly immunotherapies, targeted biologics, and precision diagnostics. These treatments, while clinically effective, can cost hundreds of thousands of dollars per patient annually, creating affordability challenges for both patients and healthcare systems. This financial burden is especially pronounced in low- and middle-income countries, where limited insurance coverage and constrained public healthcare budgets restrict access. Even in developed markets, payers are increasingly scrutinizing cost-effectiveness, often delaying or limiting reimbursement. High R&D costs, complex manufacturing (especially for biologics), and regulatory hurdles further inflate prices. As a result, many promising therapies face slow adoption despite clinical success. While pricing remains the central restraint, additional barriers include disparities in biomarker testing infrastructure, shortage of trained oncologists in rural regions, and the risk of immune-related adverse events, which can lead to treatment discontinuation or increased hospitalization, impacting both clinical outcomes and market penetration.

Opportunites

One key opportunity in the market lies in the expansion of immuno-oncology therapies into early-stage and multiple solid tumor types. Initially approved for metastatic cancers, immune checkpoint inhibitors like pembrolizumab and nivolumab are now being evaluated, and increasingly approved, for adjuvant and neoadjuvant use in earlier stages of cancers such as non-small cell lung cancer (NSCLC), melanoma, and bladder cancer. This broadens the eligible patient base and significantly increases market potential. Pharmaceutical companies are accelerating clinical trials exploring combinations of immunotherapy with chemotherapy, radiation, and novel agents like antibody-drug conjugates (ADCs) to improve outcomes in solid tumors. Furthermore, approvals of tumor-agnostic treatments (e.g., for NTRK or MSI-H mutations) open doors for broader applications across rare and difficult-to-treat cancers. While this expanding role of immunotherapy forms the core opportunity, other promising areas include biosimilars of key biologics, emerging markets adoption, mRNA-based cancer vaccines, and digital therapeutics that enhance treatment adherence and outcomes.

Trends

The most significant current trend in the market is the rapid integration of advanced diagnostics, particularly liquid biopsies and AI-driven tools, which enable precision treatment and real-time disease monitoring. Liquid biopsies that detect circulating tumor DNA (ctDNA) are gaining ground for early detection, minimal residual disease (MRD) monitoring, and relapse prediction, often identifying recurrences up to two years before imaging. Coupled with this, AI-powered imaging and genomics platforms are transforming diagnostic accuracy and treatment planning. Next-generation sequencing (NGS) panels and molecular profiling integrated with AI tools are enabling clinicians to match patients to targeted or immune-oncology therapies more effectively. For example, ASCO 2025 highlighted ctDNA liquid biopsies for lung and breast cancer, and AI tools for prostate cancer patient selection. Meanwhile, innovations in immuno-oncology (e.g., ADCs, CAR?T, mRNA vaccines) and the approval of tumor-agnostic therapies are complementing diagnostic advances. These trends collectively signal a shift toward personalized, data-driven care in solid tumor management.

Solid Tumor Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2024

US$ 4,832.3 million

Market Size in 2031

US$ 5,589.0 million

Market CAGR

2.1%

By Tumor Type

  • Benign Tumor
  • Malignant Tumor

By Therapy Type

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Tyrosine kinase inhibitors
  • Proteasome inhibitor
  • Hedgehog pathway inhibitor
  • Others

By Drug Class

  • Alkylating Agents
  • Antimetabolites
  • Topoisomerase Inhibitors
  • Proteasome Inhibitors
  • Monoclonal Antibodies
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Region

  • North America (USA, Canada)
  • Europe (Germany, UK, France, Spain, Italy , Rest of Europe)
  • The Asia Pacific (China, India, Japan, Australia, South Korea, Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America)
  • MEA (Saudi Arabia, UAE, South Africa, Rest of MEA)

Analyst Review

According to a PBI Analyst, the market is witnessing robust growth driven by rising cancer incidence, increased adoption of targeted therapies, and rapid advancements in diagnostics like liquid biopsy and AI-powered genomics. Immuno-oncology is expanding beyond metastatic settings into early-stage treatments, unlocking significant market potential. However, high therapy costs and access disparities in low- and middle-income countries remain key challenges. Regulatory support, growing biosimilar entry, and digital health integration are helping to balance innovation with affordability. Overall, the market is transitioning toward personalized, precision-based care, offering strong investment opportunities across diagnostics, biologics, and combination treatment pipelines for the years ahead.

Key Features of the Report

  • The solid tumor market report provides granular level information about the Market size, regional Market share, historic Market (2020-2024), and forecast (2025-2031)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key Market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the Market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the Market.
  • The report provides a plethora of information about Market entry strategies, regulatory framework, and reimbursement scenarios.
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis.

Download Free Sample Report

Frequently Asked Questions

Solid tumor market size was valued at US$ 4,832.3 million in 2024 and is projected to reach US$ 5,589.0 million by 2031 at a CAGR of 2.1% from 2025-2031.

Rising global cancer incidence and the shift to targeted and immuno-oncology therapies are primary growth drivers.

Targeted therapies dominate due to high efficacy and wide applicability in common solid tumors.

Market is segmented based on tumor type, therapy type, drug class, route of administration, end use, and region.

North America dominates the market due to the strong R&D, early adoption of advanced treatments, and robust healthcare infrastructure.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Solid Tumor Market Introduction 
2.1.Global Solid Tumor Market  - Taxonomy
2.2.Global Solid Tumor Market  - Definitions
2.2.1.Tumor Type
2.2.2.Therapy Type
2.2.3.Drug Class
2.2.4.Route of Administration
2.2.5.Region
3.Global Solid Tumor Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Solid Tumor Market Analysis, 2020 - 2024 and Forecast 2025 - 2031
4.1.  Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Solid Tumor Market  By Tumor Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
5.1. Benign Tumor
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Malignant Tumor
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Solid Tumor Market  By Therapy Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
6.1. Chemotherapy
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Immunotherapy
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Targeted Therapy
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Tyrosine kinase inhibitors
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Proteasome inhibitor
6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Hedgehog pathway inhibitor
6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. Others
6.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
7.Global Solid Tumor Market  By Drug Class, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
7.1. Alkylating Agents
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Antimetabolites
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Topoisomerase Inhibitors
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Proteasome Inhibitors
7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Monoclonal Antibodies
7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
7.6. Others
7.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.6.3. Market Opportunity Analysis 
8.Global Solid Tumor Market  By Route of Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
8.1. Oral
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Parenteral
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Others
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Solid Tumor Market  By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
10.1. Tumor Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Benign Tumor
10.1.2.Malignant Tumor
10.2.  Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Chemotherapy
10.2.2.Immunotherapy
10.2.3.Targeted Therapy
10.2.4.Tyrosine kinase inhibitors
10.2.5.Proteasome inhibitor
10.2.6.Hedgehog pathway inhibitor
10.2.7.Others
10.3.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Alkylating Agents
10.3.2.Antimetabolites
10.3.3.Topoisomerase Inhibitors
10.3.4.Proteasome Inhibitors
10.3.5.Monoclonal Antibodies
10.3.6.Others
10.4.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Oral
10.4.2.Parenteral
10.4.3.Others
10.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
11.1. Tumor Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Benign Tumor
11.1.2.Malignant Tumor
11.2.  Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Chemotherapy
11.2.2.Immunotherapy
11.2.3.Targeted Therapy
11.2.4.Tyrosine kinase inhibitors
11.2.5.Proteasome inhibitor
11.2.6.Hedgehog pathway inhibitor
11.2.7.Others
11.3.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Alkylating Agents
11.3.2.Antimetabolites
11.3.3.Topoisomerase Inhibitors
11.3.4.Proteasome Inhibitors
11.3.5.Monoclonal Antibodies
11.3.6.Others
11.4.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Oral
11.4.2.Parenteral
11.4.3.Others
11.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
12.1. Tumor Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Benign Tumor
12.1.2.Malignant Tumor
12.2.  Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Chemotherapy
12.2.2.Immunotherapy
12.2.3.Targeted Therapy
12.2.4.Tyrosine kinase inhibitors
12.2.5.Proteasome inhibitor
12.2.6.Hedgehog pathway inhibitor
12.2.7.Others
12.3.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Alkylating Agents
12.3.2.Antimetabolites
12.3.3.Topoisomerase Inhibitors
12.3.4.Proteasome Inhibitors
12.3.5.Monoclonal Antibodies
12.3.6.Others
12.4.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Oral
12.4.2.Parenteral
12.4.3.Others
12.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
13.1. Tumor Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Benign Tumor
13.1.2.Malignant Tumor
13.2.  Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Chemotherapy
13.2.2.Immunotherapy
13.2.3.Targeted Therapy
13.2.4.Tyrosine kinase inhibitors
13.2.5.Proteasome inhibitor
13.2.6.Hedgehog pathway inhibitor
13.2.7.Others
13.3.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Alkylating Agents
13.3.2.Antimetabolites
13.3.3.Topoisomerase Inhibitors
13.3.4.Proteasome Inhibitors
13.3.5.Monoclonal Antibodies
13.3.6.Others
13.4.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Oral
13.4.2.Parenteral
13.4.3.Others
13.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
14.1. Tumor Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Benign Tumor
14.1.2.Malignant Tumor
14.2.  Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Chemotherapy
14.2.2.Immunotherapy
14.2.3.Targeted Therapy
14.2.4.Tyrosine kinase inhibitors
14.2.5.Proteasome inhibitor
14.2.6.Hedgehog pathway inhibitor
14.2.7.Others
14.3.  Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Alkylating Agents
14.3.2.Antimetabolites
14.3.3.Topoisomerase Inhibitors
14.3.4.Proteasome Inhibitors
14.3.5.Monoclonal Antibodies
14.3.6.Others
14.4.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Oral
14.4.2.Parenteral
14.4.3.Others
14.5.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Abbott Laboratories Inc.
15.2.2.Biogen Inc.
15.2.3.AstraZeneca PLC
15.2.4.Boehringer Ingelheim GmbH
15.2.5.Amgen Inc.
15.2.6.Bristol-Myers Squibb Company
15.2.7.Stemline Therapeutics, Inc.
15.2.8.Baxter International Inc.
15.2.9.Eli Lilly and Company
15.2.10.GlaxoSmithKline PLC
15.2.11.Hoffmann-La Roche AG
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • Abbott Laboratories Inc.
  • Biogen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Stemline Therapeutics, Inc.
  • Baxter International Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche AG

Related Industry Reports